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The role of FDG-PET/CT in preoperative
staging of sentinel lymph node biopsy-
positive melanoma patients
Evan C. Frary1* , Dorte Gad4, Lars Bastholt5 and Søren Hess1,2,3
Abstract
Background: On April 1, 2015, Odense University Hospital (OUH) began a new diagnostic strategy, wherein all
malignant melanoma (MM) patients in the Region of Southern Denmark with a positive sentinel lymph node
biopsy (SLNB) underwent FDG-PET/CT preoperatively prior to lymph node dissection (LND). The purpose of this
study is to determine FDG-PET/CT’s efficacy in finding distant metastasis in the first year after the implementation
of this new strategy, and to what extent these findings influence subsequent diagnostic testing and treatment in
this patient group. We conducted a retrospective multicenter cohort study which included all patients with MM
from all hospitals in the Region of Southern Denmark from April 1, 2015 to April 1, 2016 found to be SLNB-positive
who subsequently underwent FDG-PET/CT. Patient information was acquired from the Danish Melanoma Database
and was cross-referenced with OUH’s patient records. The data was analyzed for a number of parameters including
FDG-PET/CT findings and treatment strategy. Median follow-up time was 7 months.
Results: A total of 47 patients were eligible from the first year of this new diagnostic strategy. One patient was
excluded due to undergoing LND prior to FDG-PET/CT. Thus, 46 patients were included in this study. Ultimately,
preoperative FDG-PET/CT neither uncovered any distant metastases nor led to any alterations in treatment
strategy in this patient group.
Conclusions: Surprisingly, this new diagnostic strategy did not find any MM metastases or uncover anything else
of relevance. FDG-PET/CT did, however, provide false positive findings in 13 % (6/46) of these patients. These
scans triggered additional, predominantly invasive, procedures, which did not ultimately have an impact on the
therapeutic strategy. Thus, these findings indicate a need for re-evaluation of this new diagnostic strategy as well
as the necessity for further clinical trials evaluating FDG-PET/CT’s utility in this clinical setting.
Keywords: Skin cancer, Melanoma, Sentinel lymph node biopsy, FDG-PET/CT, Staging
Background
The incidence of malignant melanoma (MM), and its
corresponding health burden, has been steadily increas-
ing over the past few decades with 232,000 new cases
diagnosed worldwide in 2012 [1]. MM’s mortality rate
varies greatly depending on the stage of the disease at
diagnosis. In the early stages of MM, the 5-year survival
rates are quite high, 97 and 92 % for stages IA and IB,
respectively. This survival rate, however, falls drastically
in the later stages of MM to between 10 and 30 % for
stage IV patients [2]. This vast difference in prognosis
underscores the importance of early diagnosis and accur-
ate staging of MM.
Positron emission tomography and computed tomog-
raphy (PET/CT) based on a radio-labeled glucose analog
known to accumulate in hypermetabolic cells (e.g., cancer
cells), F-18-fluordeoxyglucose (FDG), is increasingly being
employed in the diagnosis, staging, and evaluation of treat-
ment response in a multitude of malignancies [3, 4]. While
sentinel lymph node biopsy (SLNB) is still considered the
reference standard for determining locoregional lymph
node metastasis [5], the role of FDG-PET/CT in the sta-
ging of MM patients has yet to be conclusively defined.
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A number of papers have suggested that for the early
stages of MM (i.e., I-II) FDG-PET/CT is only of limited
diagnostic value, due to its low sensitivity in detecting
microscopic lymphatic disease [6–8]. It has been posited,
however, that in advanced stages of MM (i.e., III-IV),
FDG-PET/CT can be of great value by locating distant
metastases, thereby influencing treatment decisions and
informing prognosis [8–12]. As the primary treatment
for stage III patients is radical lymph node dissection
(LND) [13], the identification of these distant metastases
prior to LND is of great importance as this treatment
becomes superfluous in stage IV metastatic patients.
Thus, LND, and its corresponding complications, can be
avoided if these metastases are found preoperatively, as
well as allowing for the swift initiation of subsequent
therapeutic strategy.
On April 1, 2015, Odense University Hospital began a
new diagnostic strategy, wherein all MM patients in the
Region of Southern Denmark with positive SLNB under-
went FDG-PET/CT preoperatively prior to LND. In this
article, we report on the efficacy of FDG-PET/CT in
finding distant metastasis in patients with SLNB-positive
MM, as applied in this new diagnostic strategy, and to
what extent this imaging modality influences subsequent
diagnostic testing and treatment.
Methods
Study population
We conducted a retrospective multicenter cohort study
which included all MM patients with positive SLNB
from all hospitals in the Region of Southern Denmark
from April 1, 2015 to April 1, 2016. The data for this
study was collected from the Danish Melanoma Data-
base (DMD), which contains information on all MM
patients in Denmark, as well as the Region of Southern
Denmark’s electronic patient record and imaging sys-
tem. The inclusion criteria for the study were a novel
diagnosis of MM, a positive SLNB for MM, and a subse-
quent FDG-PET/CT prior to LND. The patients’ medical
records were reviewed and cross-referenced with the
DMD for basic information comprising age and sex as
well as primary tumor characteristics (location, histo-
logical type, Clark’s level, Breslow’s depth, and ulceration
presence), SLNB findings (location, number of positive
sentinel lymph nodes (SLN) removed, and total number
of SLN removed), TNM stage, FDG-PET/CT findings, and
finally the additional tests and/or changes in treatment
triggered due to the FDG-PET/CT findings. Follow-up
analysis was performed by reviewing the patients’ elec-
tronic records with a median of 7 months (range 3–13).
Due to the retrospective nature of the study, informed
consent was not required by Danish Law, but the study
was approved by the Danish Data Protection Agency
(journal nr. 15/48420) and the Danish Board of Health
in accordance with Danish legislation.
FDG-PET/CT-protocol
All FDG-PET/CT scans were performed routinely in ac-
cordance the department’s standard protocol, i.e., with
scans from vertex of the skull to the proximal femurs
or the entire body if the primary lesion was in the lower
extremities. The local protocol is in accordance with
guidelines from the European Association of Nuclear
Medicine [14]. All examinations were performed on a
GE Discovery VCT, a GE Discovery STE, a GE Discovery
RX, or Discovery 690 PET/CT scanner (GE Healthcare,
Milwaukee, WI, USA). The CT imaging was performed
as a low-dose CT scan without contrast enhancement.
Data were reconstructed with a standard filter into
transaxial slices with a field of view of 50 cm, matrix
size of 512 × 512 (pixel size 0.98 mm), and a slice thick-
ness of 3.75 mm. The CT scan was followed immediately
by a PET scan performed using a standard whole-body
acquisition protocol with six or seven bed positions and
an acquisition time of approx. 2.5 min per bed position
(adjusted to patient size). The scan field of view was
70 cm. Attenuation correction was performed from the
CT scan. The PET data were reconstructed into trans-
axial slices with a matrix size of 128 × 128 or 256 × 256
(Discovery 690) and a slice thickness of 3.75 mm using
iterative 3D OS-EM (with varying iterations and sub-
sets), and displayed in coronal, transverse, and sagittal
planes. Corrections for attenuation, randoms, dead time,
and normalization were done inside the iterative loop. At
the time of FDG administration, all patients had fasted
for at least 6 h. PET/CT image acquisition commenced
60 ± 5 min. after the administration of a weight adjusted
dose of 4 MBq/kg (110 μCi/kg) FDG (min. 200 MBq
(5 mCi) and max. 400 MBq (10 mCi)). Analysis of the
PET and fused PET/CT data was done using a GE Advan-
tage Workstation v. 4.4 or a GE Advantage Server 2.0 (GE
Healthcare). The fused PET/CT imaging analysis was
performed as a routine interpretation by a nuclear
medicine specialist.
Imaging analysis
All FDG-PET/CT findings were confirmed or rejected
using histological analysis and/or follow-up as the refer-
ence standard. Increased FDG-uptake suggestive of metas-
tasis was defined as a true positive result if subsequently
confirmed via histological analysis and false positive if sub-
sequently ruled out by histological analysis or, as in one
case, by a pulmonologist. If there was no abnormal FDG-
uptake suggestive of metastasis, a true negative result
was defined as no metastasis uncovered in the follow-
up period and false negative where a metastasis was
subsequently discovered in the follow-up period.
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Statistical analysis
FDG-PET/CT’s diagnostic efficacy, and the corresponding
95 % confidence interval, was calculated with respect to
sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV), and accuracy. All statistical
analyses were done in STATA/IC 14.0 for Windows.
Results
Forty-seven consecutive SLNB-positive MM patients were
eligible for this study. Due to scheduling conflicts, one
patient underwent LND prior to FDG-PET/CT and was
therefore not included. Thus, a total of 46 patients, 26
males and 20 females with a median age of 61 (range
26–82), were included in our retrospective patient cohort.
Primary tumor characteristics
The locations of the patients’ primary tumors were as
follows: head and neck (n = 1), trunk (n = 21), upper ex-
tremities (n = 7), and lower extremities (n = 16). After
histological analysis, the diagnoses were: superficial spread-
ing melanoma (n = 31), nodular melanoma (n = 9), acral
lentiginous melanoma (n = 3), spitzoid melanoma (n = 1),
and melanoma of undetermined type (n = 1). The vast
majority of the patients had a Clark’s level of IV (n =
37), the rest had a Clark’s level of either V (n = 3), III
(n = 4), or II (n = 1). The Breslow’s depths were divided
into four intervals and tallied: ≤1.00 mm (n = 2), 1.01–
2.00 mm (n = 16), 2.01–4.00 mm (n = 23), and >4.00 mm
(n = 4). Histological analysis of the primary tumor also re-
vealed ulceration in 18/45 (40 %) and mitoses in 21/45
(47 %). Note, one patient had two simultaneous cutaneous
tumors and the primary tumor could not be conclusively
determined; thus, these tumors were not included in the
tumor tally. Table 1 provides a description of the patients’
primary tumor characteristics.
SLNB findings
With respect to the patients’ SLNB, the procedures were
performed on lymph nodes located in the axilla (n = 25),
the inguinal canal (n = 24), the neck (n = 3), and the pop-
liteal fossa (n = 1). All patients had at least one positive
SLNB. In total, 120 lymph nodes were removed from the
entire cohort and 65 of them (54 %) were determined to
be positive for MM metastasis. The mean tumor diam-
eter found for a positive SLN was 0.90 mm. Perinodal
growth was seen in three patients. The patients’ prelim-
inary staging, prior to PET/CT evaluation, were found
to be stage IIIA (n = 24), IIIB (n = 18), and IIIC (n = 4).
With respect to TNM staging, the patients’ T stages were
diagnosed as T1 (n = 2), T2 (n = 20), T3 (n = 20), and T4
(n = 4), while the N stages were N0 (n = 0), N1 (n = 32),
N2 (n = 12), and N3 (n = 2). Note, with respect to the
aforementioned patient with two simultaneous cutaneous
tumors, the tumor with the higher T staging was used. No
distant MM metastases were diagnosed; thus, all patients
had M0-disease. Table 2 provides a description of the
patients’ SLNB findings and preliminary staging as well
as final staging.
PET/CT findings
Increased FDG-uptake suggestive of distant metastasis
was found in 7/46 patients (15 %). One of these was de-
termined to be progression of pre-existing concomitant
squamous-cell carcinoma of the lungs and not meta-
static MM. The remaining 6/46 patients (13 %) had an
increased FDG-uptake suggestive of MM metastasis, and
all six triggered additional diagnostic testing. Table 3 pro-
vides an overview of the positive FDG-PET/CT findings
and subsequent tests performed.
The first patient had increased uptake in the axillary
lymph nodes as well as in the colon and rectum (Fig. 1)
and was referred to a colonoscopy where one benign
polyp was resected. Patient number two had bilateral lung
infiltrates upon FDG-PET/CT imaging (Fig. 2), and was
referred to a lung specialist where no further testing was
Table 1 Primary tumor characteristics
Primary tumor characteristics No. (n = 45)a
Location
Head and neck 1
Trunk 21
Upper extremity 7
Lower extremity 16
Melanoma type
Superficial spreading 31
Nodular 9
Acral lentiginous 3
Spitzoid 1
Undetermined 1
Clark’s level
I 0
II 1
III 4
IV 37
V 3
Breslow’s thickness
≤1.00 mm 2
1.01–2.00 mm 16
2.01–4.00 mm 23
>4.00 mm 4
Ulceration present 18
Mitoses present 20
aOne patient had two simultaneous cutaneous tumors and, as it was unclear
as to which was the primary tumor, was not included in this table
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undertaken. The third patient was also referred to a lung
specialist due to increased FDG-uptake in the lymph
nodes in the mediastinum and lung hili (Fig. 3). The
patient underwent endobronchial ultrasound (EBUS)
biopsy of the suspect nodes, and no cancer was found.
Patient number four had unilateral increased uptake in
the thyroid gland (Fig. 4) and was referred to an ear,
nose, and throat (ENT) specialist where an ultrasound-
guided biopsy was subsequently performed revealing a
benign adenoma. The remaining two patients had in-
creased uptake in the sigmoid colon (Figs. 5 and 6). After
referral to a colonoscopy, a polyp was found and deter-
mined to be benign in both cases. None of these add-
itional tests ultimately led to any alteration in the patients’
melanoma treatment, and all the patients subsequently
underwent LND as planned, except in four instances
where the patient refused treatment. Five out of the 42
patients (12 %) who ultimately underwent LND were
found to have a positive non-sentinel lymph node (NSLN).
The patients’ final staging, i.e., post-LND, remained
unchanged from their preliminary staging (i.e., IIIA
(n = 24), IIIB (n = 18), and IIIC (n = 4)). Table 2 pro-
vides a description of the LND findings and the
patients’ final staging.
Ultimately, the analysis of this new FDG-PET/CT diag-
nostic strategy in this patient group showed 0 true posi-
tives (TP), 6 false positives (FP), 0 false negatives (FN),
and 40 true negatives (TN). Further statistical evaluation
of FDG-PET/CT’s diagnostic probabilities with respect to
MM metastasis provided: sensitivity not estimable (due to
TP and FN being 0), specificity 87 % (74–95 %), PPV 0 %
(CI 0–46 %), NPV 100 % (CI 91–100 %), and accuracy
87 % (CI 74–95 %). Note, while we were able to calculate
all the diagnostic probabilities, other than sensitivity,
NPV is the only probability of real practical value in
this instance.
Discussion
The results presented above comprise our experience
from the first year after the implementation of a new diag-
nostic strategy of performing preoperative FDG-PET/CT
in 46 consecutive SLNB-positive MM patients prior to
LND. While 12 % of patients who underwent LND had
Table 2 SLNB findings, preliminary staging, LND findings,
and final staging
SLNB findings, preliminary staginga, LND findings, and final stagingb
SLNB findings
SLNB location
Axillary lymph nodes 24
Inguinal lymph nodes 24
Cervical lymph nodes 3
Popliteal fossa lymph nodes 1
SLN
Removed
Total 120
Per patient median (range) 2 (1-5)
Positive
Total 65
Per patient median (range) 1 (1-5)
SLN tumor diameter mean (mm) 0.90
Perinodal growth 3
Preliminary staging
IIIA 24
IIIB 18
IIIC 4
LND findings
NSLN
Removed
Total 564
Per patient median (range) 12 (3-45)
Positive
Total 5
Per patient median (range) 0 (0-1)
Final staging
IIIA 24
IIIB 18
IIIC 4
aPreliminary staging was done post-SLNB and pre-PET/CT
bFinal staging was done post-LND
SLNB sentinel lymph node biopsy, LND lymph node dissection, SLN sentinel
lymph node, NSLN non-sentinel lymph node
Table 3 PET/CT findings in patients with increased FDG-uptake suggestive of MM distant metastasis (n = 6)
No. Age/sex FDG-uptake location(s) Additional tests Distant metastasis Treatment outcome
1 45/M Axillary LN, colon, rectum Colonoscopy, polyp resection No Lymph node dissection
2 60/F Lung infiltrates bilaterally Pulmonologist referral No Lymph node dissection
3 54/M Mediastinum LN, hilar LN EBUS biopsy No Lymph node dissection
4 74/F Thyroid gland Ultrasound-guided biopsy No Lymph node dissection
5 71/M Sigmoid colon Colonoscopy, polyp resection No Lymph node dissection
6 74/M Sigmoid colon Colonoscopy, polyp resection No Lymph node dissection
MM malign melanoma, LN lymph nodes
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positive NSLN, similar to the rate (10–17 %) found in the
literature [15–17], this novel approach did not find any
MM metastases or lead to any alterations in treatment
strategy. FDG-PET/CT did, however, provide FP findings
in 13 % (6/46) of these patients. This triggered additional,
predominantly invasive, procedures, which did not ul-
timately have an impact on the therapeutic strategy.
While this relatively high FP rate in FDG-PET/CT has
been seen previously in similar MM patient populations
[7, 18], it does not automatically preclude FDG-PET/
CT’s utility in these patients. The FP rate must instead
be weighed against the potential for overlooking a distant
metastasis which can greatly impact patient prognosis and
treatment options. However, our results may provide an
incentive to re-evaluate of the use of FDG-PET/CT in this
patient population.
This diagnostic strategy was originally initiated in re-
sponse to literature indicating FDG-PET/CT’s value in
preoperative screening of SLNB-positive MM patients.
A number of studies have shown FDG-PET/CT, in general,
is the superior imaging modality in diagnosing distant me-
tastasis in MM patients, compared to other conventional
modalities such as ultrasonography, whole-body MRI,
CT alone, or PET alone, with a sensitivity, and specifi-
city as high as 97 % [9, 19, 20]. More specifically, the
current consensus in the literature also suggests that
the timing of FDG-PET/CT scans is important, as it
can have the most significant impact on subsequent
Fig. 1 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in the
colon and rectum (arrow)
Fig. 2 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in lung
infiltrates (arrow)
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treatment decisions if undertaken prior to treatment
initiation (e.g., before LND) [6, 8, 10–12, 21, 22]. For
example, in one of the first studies on FDG-PET/CT’s
impact on predominantly later stage (i.e., III-IV) MM pa-
tients, Gulec et al. found FDG-PET/CT imaging led to a
change in treatment in 49 % (24/49) [21]. Subsequent
studies, such as Schule et al. and Bronstein et al., also sup-
ported FDG-PET/CT’s utility in later-stage MM patients
finding that it led to significant therapeutic alterations in
59 % (31/52) and 12 % (4/33), respectively [11, 22].
However, these aforementioned studies evaluated a
different patient population and, thus, may explain the
differences as compared to our results. Our study in-
cluded only stage III MM patients who were scanned
shortly after a positive SLNB, whereas Gulec et al.,
Schule et al., and Bronstein et al. all included advanced
MM patients with both stages III and IV [11, 21, 22].
This difference in sample populations is quite important
as patients with established distant metastases are much
more likely to have additional distant metastases than pa-
tients diagnosed only with locoregional metastases.
Additionally, as in our study, a number of more recent
articles have also supported a re-evaluation of FDG-PET/
CT’s use in primary staging of SLNB-positive MM patients.
A systematic review from Shröer-Günther et al. found that,
although FDG-PET/CT’s diagnostic accuracy appeared to
increase in higher stages of MM, there was no evidence of
benefit to the patient found when FDG-PET/CT is used in
primary staging [23]. Several other studies have also ques-
tioned FDG-PET/CT’s usefulness in routine scanning of
Fig. 3 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in the
hilar lymph nodes (arrow)
Fig. 4 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in the
thyroid gland (arrow)
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SLNB-positive MM patients [18, 24–26]. Two of these
studies, Scheier et al. and Wagner et al., both reported
on a patient population almost identical to ours involv-
ing 46 SLNB-positive MM patients where FDG-PET/
CT was utilized in the initial staging to locate distant
metastases [18, 24]. Scheier et al. found that 33 % (15/46)
of these patients had abnormal uptake suggestive of MM
metastasis, but only 7 % (3/46) were ultimately found to
have a metastasis which lead to a change in treatment
[18]. Wagner et al. found 13 % (6/46) with abnormal up-
take, none of which were ultimately confirmed as a MM
metastasis [24]. These articles reinforce our findings that
FDG-PET/CT may not be beneficial in newly diagnosed
asymptomatic SLNB-positive MM patients. Table 4 pro-
vides a list of the relevant aforementioned original articles
and their findings.
The main strengths of this study are twofold. Firstly,
the consecutive multicenter patient cohort is highly
Fig. 5 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in the
sigmoid colon (arrow)
Fig. 6 a Coronal-fused FDG-PET/CT showing the region of interest
(circle). b Axial-fused FDG-PET/CT showing increased uptake in the
sigmoid colon (arrow)
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representative of the region’s patient population with-
out selection bias. Secondly, FDG-PET/CT showed a
very high NPV. While FDG-PET/CT did not lead to
any alterations in treatment strategy, it did correctly
rule out distant metastases in all patients. This high
NPV (i.e., 100 % with CI 91–100 %) is important as it
strengthens the prognosis and helps ensure that the
subsequent LND is the appropriate treatment.
There were, however, also a number of limitations in
our study. One was the scanning protocol itself. The
routine scan field was from the vertex of the skull to the
proximal femur in patients where the primary lesion was
not located in the lower extremities, i.e., in essence only
two-thirds of the body is covered. Thus, in these patients,
the potential for metastasis distal to the proximal femur is
completely ignored, and this may inadvertently increase
the number of FN scans. Although previous studies seem
to indicate that the inclusion of the lower extremities is of
limited benefit in MM patients [27, 28], a scanning proto-
col which routinely includes the entire body, regardless of
primary lesion location, would eliminate this issue entirely.
Another matter in our standard MM scan protocol is the
use of low-dose non-contrast-enhanced CT only. It is
conceivable that contrast-enhanced CT could lead to
additional metastatic findings. However, the added value
of contrast-enhanced CT is controversial as some studies
have indicated an added value due to increased sensitivity
in MM [29], while other studies in cancer patients in
general have shown no additional clinically significant
effect [30, 31].
While FDG-PET/CT correctly ruled out distant metasta-
sis in all the patients with a NPV of 100 % (CI 91–100 %),
our study’s relatively short follow-up period, median
7 months (range 3–13), lessens its conclusive power.
For example, Wagner et al. found 12 % (5/40) of FDG-
PET/CT to be FN after 12 months follow-up [24]. A
longer follow-up period would have strengthened the
reliability of our study’s high NPV. Finally, the limited
number of patients and the retrospective nature of the
study, albeit very similar in scope and size as a number
of other comparable studies, restrict the conclusions that
can be drawn. While a re-evaluation of the current recom-
mended diagnostic strategy is warranted based on the
findings from our study, further research in the form of a
randomized clinical trial would be of great benefit for a
more definitive determination of the true value of FDG-
PET/CT in this clinical setting.
Conclusions
Surprisingly, and contrary to the preponderance of evidence
in the literature, this novel diagnostic strategy revealed no
distant MM metastases or anything else of relevance during
its first year. FDG-PET/CT did, however, trigger a number
of additional diagnostic procedures, none of which led to a
change in treatment or the diagnosis of any other serious
illness. Although our patient population is limited, these
findings indicate a need for re-evaluation of the diagnostic
strategy including considerations about optimal scan proto-
col and CT procedure as well as further evaluation in a
randomized clinical trial.
Abbreviations
LND: Lymph node dissection; MM: Malignant melanoma; NPV: Negative
predictive value; OUH: Odense University Hospital; PPV: Positive predictive
value; SLN: Sentinel lymph node; SLNB: Sentinel lymph node biopsy
Table 4 Relevant original articles
Author Study design Included Patient population Diagnostic test(s) Diagnostic evaluation Findings
PET/CT Recommended
Gulec et al. [21] Retrospective 49 patients MM patients
46 stage III/IV
3 stage II (high risk)
FDG-PET/CT vs.
CT plus brain MRI
Treatment change
in 49 %
FDG-PET/CT better than
CT plus brain MRI for
determining extent of
disease
Bronstein et al. [22] Prospective 32 patients MM patients
Clinically evident III
Oligometastatic IV
FDG-PET/CT Treatment change
in 12 %
FDG-PET/CT of use
preoperatively in
surgically treatable
metastatic melanoma
Schule et al. [11] Retrospective 52 patients
in primary
staging group
MM patients stages
III-IV
FDG-PET/CT vs.
CT alone
Treatment change
in 59 %
FDG-PET/CT better than
CT alone for primary
staging
PET/CT not recommended
Wagner et al. [24] Retrospective 46 patients MM patients with
positive SLNB
PET/CT Treatment change
in 0 %
PET/CT provides no
benefit for this patient
group
Scheier et al. [18] Retrospective 46 patients MM patients with
positive SNLB
PET/CT Treatment change
in 7 %
PET/CT not recommended
for asymptomatic MM
patients with positive
SLNB micrometastasis
MM malignant melanoma, SNLB sentinel lymph node biopsy
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